N/A
N=150
Generation of Prediction Equations for BIA of the Elderly
Healthy Elderly
Bottom Line
View on ClinicalTrials.gov: NCT04028648 ↗Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Feb 2022
Primary outcome: Primary: Total Body Water — 1.85 liter
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Seca GmbH & Co. Kg.
- Primary completion
- Jan 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Body Water |
1.85 | — |
| PRIMARY Extracellular Water |
0.74 | — |
| PRIMARY Fat-free Mass |
2.20 | — |
| PRIMARY Skeletal Muscle Mass |
2.07 | — |
| PRIMARY Visceral Adipose Tissue |
0.92 | — |
Summary
The objective of the study is to develop prediction equations for calculating Fat-Free Mass FFM, Total Body Water TBW, Extracellular Water ECW, Visceral Adipose Tissue VAT, total Skeletal Muscle Mass SMM and segmental SMM in a group of elderly. The prediction equations are based on linear regression analysis between the gold standard reference methods Air Displacement Plethysmography ADP, Dual-energy X-ray Absorptiometry DXA, Magnet Resonance Imaging MRI, Deuterium dilution method (D2O) and Sodium Bromide dilution method (NaBr) on the one hand and bioelectrical impedance measurements on the other hand.
Multi-frequency bioimpedance is measured for all body segments: right arm, left arm, right leg, left leg, trunk, right body side and left body side using the seca mBCA 515 in standing position and the seca mBCA 525 in standing and lying position.
Eligibility Criteria
Inclusion Criteria
- male and female subjects older than 60 years,
- stable medication (no changes during the past 6 months),
- subjects need to be able to sign the informed consent and privacy policy
Exclusion Criteria
- acute disease
- intake of diuretics
- wearing of support stockings
- edema diagnosed by inspection and palpation of lower limbs
- paralysis e.g. after a stroke
- neurodegenerative diseases e.g. ALS
- tumors in treatment
- amputation
- electronic implants e.g. pacemaker
- under the skin applied injection systems (e.g. insulin pumps or pain pumps)
- probands who cannot provide an ICF by themselves
- probands who might be dependent from the sponsor or the investigation site
- current alcohol abuse
- active prostheses
- electronic life-support systems, e.g. artificial heart, artificial lung
- portable electronic medical devices, e.g. ECG devices or infusion pumps
- metallic implants
- cochlea implants und heart valves prothesis (e.g. Starr-Edwards-Prothesis)
- vessel clips in the brain or medulla applied before 1995
- defeatable pumps
- catheter
- iron or metallic parts in the body (e.g. shard of metal)
- dental braces
- magnetic tooth implants
- not removeable piercings
- extensive tattoos
Data sourced from ClinicalTrials.gov (NCT04028648). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.